Journal September 26, 2026 7 min read

How the Blood-Brain Barrier Changes with Age

The blood-brain barrier (BBB) is the neurovascular unit's selective interface between circulating blood and the central nervous system. This page summarises what laboratory and clinical research reports about age-related

peptides-pro Editorial

The blood-brain barrier (BBB) is the selective, semi-permeable interface separating circulating blood from the central nervous system parenchyma. It is not a single membrane but a functional unit — the neurovascular unit — comprising brain endothelial cells (BECs) joined by tight junctions, supported by pericytes, astrocytic end-feet, and a basement membrane. In the research literature the term is used interchangeably with "neurovascular unit" when the cellular contributors are being discussed together. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for the BBB as a structure, because it is a tissue-level barrier rather than a single molecular entity; the identifiers that appear in the cited work are cellular and protein-level, including senescence-associated beta-galactosidase (SA-β-gal), transferrin receptor (TfR), insulin-like growth factor 1 receptor, myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, chondroitin sulfate proteoglycan 5, and the matricellular protein SPARC.

The work summarised here centres on receptor-mediated transcytosis (RMT) as the principal transport route across the barrier, together with the senescence, circadian, and neuroimmune signalling families that are reported to modulate barrier integrity with age.

Research Studies

Brain endothelial cell senescence and nanoparticle-mediated senolysis in aged BBB models

A study of polymeric nanoparticles loaded with the senolytic agent navitoclax reported that the blood-brain barrier experiences dysfunction during physiological aging, and that brain endothelial cell senescence is a key factor contributing to that impairment [8]. The nanoparticles were taken up by both proliferative and senescent BECs, but were degraded only in the senescent cells, where senescence-associated beta-galactosidase (SA-β-gal) is present, releasing the drug to induce cell death. The authors reported that the nanoparticles effectively and selectively eliminated senescent BECs in their model system [8]. This is a laboratory finding in cell-based and animal models; it does not establish an effect in humans.

Dual targeting of BBB and intra-brain proteins for antibody delivery and retention

Efficient delivery of therapeutic antibodies to the brain has increasingly been achieved using receptor-mediated transcytosis approaches such as transferrin receptor (TfR)-mediated shuttle systems [4]. A more recent focus has been brain retention, because TfR shuttles are cleared rapidly from the brain. The proposed approach combines binding to intra-brain proteins — myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5 — for sustained retention, with binding to BBB proteins including TfR and insulin-like growth factor 1 receptor [4]. This work is preclinical and describes an engineering strategy rather than an observed age-related change in humans.

Circulating placental growth factor and BBB disruption in glioblastoma

Angiogenesis in glioblastoma (GBM) is a multifactorial process, and blood-brain barrier disruption enables the detection of circulating mediators [6]. In a prospective observational study of 54 patients with IDH-wildtype GBM, plasma samples collected at diagnosis and recurrence were analysed using a multiplex panel of angiogenesis mediators, and associations with clinical, radiological, molecular, and treatment-related variables were assessed [6]. The study examined circulating placental growth factor (PlGF) as a prognostic biomarker in this high-risk population. The population here is adults with IDH-wildtype glioblastoma, not a healthy aging cohort.

SPARC and delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage

Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein involved in neurovascular injury and blood-brain barrier dysfunction [10]. A study reported that elevated acute-phase plasma SPARC levels precede the development of angiographic vasospasm and delayed cerebral ischemia (DCI) in severe aneurysmal subarachnoid haemorrhage (aSAH), a condition in which DCI remains a major determinant of poor outcome [10]. The population is patients with severe aSAH.

Transcutaneous auricular vagal nerve stimulation and radiation necrosis-related cerebral edema

A multi-centre, randomised, blinded trial is evaluating transcutaneous auricular vagal nerve stimulation (taVNS) for radiation necrosis-related cerebral edema [1]. Consenting and eligible patients are assigned to a treatment arm or a sham arm. In both arms, imaging is performed and tissue and blood are collected to assess changes in the area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability [1]. The outcome measures are therefore direct readouts of barrier permeability in a clinical population.

Cerebrolysin after extended-window endovascular thrombectomy

Acute ischemic stroke caused by blockage of a large brain artery can lead to severe disability, and endovascular thrombectomy can benefit selected patients treated 6 to 24 hours after onset, though some remain disabled even when the blocked artery is successfully reopened [3]. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery. A multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery [3].

Circadian clock genes and barrier-relevant neurodegenerative cascades

Alzheimer's disease (AD), the most prevalent form of dementia, has been increasingly associated with disruptions in circadian rhythms and sleep-wake regulation [7]. Mechanistic studies suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis, with disruption reported in circadian-regulated pathways including BMAL1-SIRT1 and NF-κB-NLRP3 signalling [7]. This is a narrative review; the mechanistic claims derive largely from preclinical work.

Low-dose ketamine and astrocyte mitochondrial preconditioning

Ketamine's antidepressant efficacy has classically been attributed to noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) on the neuronal postsynaptic membrane, reducing excessive Ca²⁺ influx through the NMDAR channel [5]. A review of the literature reports that recent evidence suggests additional physiological changes, including preconditioning of astrocyte mitochondria, with adenosine, humanin, and melatonin upregulation and efflux proposed as mediators [5]. Astrocytes are a component of the neurovascular unit, so this work is relevant to barrier biology, but it does not itself measure barrier permeability.

Protein-energy wasting and anabolic resistance in advanced chronic kidney disease

Protein-energy wasting (PEW) drives significant morbidity and mortality in advanced chronic kidney disease (CKD), and a subset of uremic patients may exhibit a defining "nutritional paradox" [2]. Unlike simple starvation, which responds to caloric and protein supplementation, CKD-associated cachexia is characterised by a potential systemic anabolic resistance that renders standard nutritional interventions — including oral supplements and intradialytic parenteral nutrition — often insufficient [2]. The proposed "sensitize-then-feed" framework models a molecular hierarchy driving this barrier to nutritional therapy [2]. The population is patients with advanced CKD.

Quantifying BBB integrity across in vitro models

Quantifying blood-brain barrier integrity from fluorescence microscopy has been limited by subjective scoring and categorical classification methods that lack reproducibility [9]. Two semi-automated image-analysis pipelines have been presented that replace manual scoring with quantitative, continuous measurement, enabling reproducible BBB phenotyping across models [9]. This is a methods contribution rather than a finding about aging.

Comparison of reported model systems and populations

Study focus	Model or population	Barrier-relevant readout
Senolytic nanoparticles [8]	Cell-based and animal BBB models	Selective elimination of senescent BECs
Dual-targeted antibodies [4]	Preclinical engineering	RMT delivery and brain retention
Circulating PlGF [6]	54 adults, IDH-wildtype GBM	Plasma angiogenesis mediators
Plasma SPARC [10]	Patients with severe aSAH	Vasospasm and DCI onset
taVNS trial [1]	Patients with radiation necrosis	Contrast enhancement, edema, permeability markers
Cerebrolysin trial [3]	Extended-window thrombectomy patients	Tissue injury after reperfusion

Neuroimmune signalling at the barrier

Neuroimmune interactions reveal that the central nervous system is dynamically integrated with peripheral immunity, with bidirectional communication mediated by microglia, astrocytes, peripheral immune cells, and the neurovascular unit through cytokines, chemokines, complement proteins, and neurotransmitters [12]. Herbal nanoparticles have separately been reviewed as a strategy in neurodegeneration, where protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction are described as co-occurring mechanisms [11]. Both are review-level sources and are cited here as background rather than as primary findings.

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.